# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹603 Cr** Q3 FY'26 (+2% QoQ) * **EBITDA:** **₹103 Cr** Q3 FY'26 (−22%) · **₹398 Cr** 9M FY'26 (22% margin) * **PAT:** **₹39 Cr** Q3 FY'26 * **Net Debt / EBITDA:** **1.0x** (as of Dec-25) * **ROCE:** **17%** (20% ex-CWIP) ## B. Revenue Trends * **Sequential Growth Despite Headwinds:** Revenue improved 2% QoQ on better product mix and post-November recovery, even as volumes remained flat. * **Premiumization Momentum:** Derivatives & Specialty business increased to **52% of revenue**, reflecting strategic shift toward higher-value products. ## C. Margin Pressure * **Near-Term Margin Compression:** EBITDA margin contracted to 17% in Q3 due to lower realizations, rising input costs, and high-cost inventory. * **CPVC-Specific Challenges:** Margins in CPVC segment fell to **17%** amid falling prices and elevated inventory costs, with recovery expected from Q4 onward. * **Sustained Underlying Profitability:** Despite pressure, 9-month EBITDA margin held at 22%, indicating relative resilience over the full period. ## D. Balance Sheet * **Leverage Improved Year-on-Year:** Net debt/EBITDA reduced significantly to 1.0x from 8x a year ago, despite a modest increase in absolute debt. ## E. Cash Flow & ROCE * **Healthy Capital Efficiency:** ROCE improved to 17% (20% ex-CWIP), signaling solid returns on deployed capital. --- # 2. Product & Segment Performance ## A. Key Figures * **Derivatives & Specialty Revenue Mix:** **52%** of total revenue (+200 bps QoQ) * **Chlorotoluene Margin Guidance:** **20–23%** expected range ## B. CPVC Business * **Capacity & Competition:** Reliance advancing with **11 Kt CPVC capacity** commissioning; Adani remains non-committal despite PVC ambitions. * **Internal R&D Focus:** Company operates a CPVC pipe pilot plant strictly for **internal testing and compounding**, with no plans for commercial pipe manufacturing or forward integration. * **Near-Term Headwinds:** CPVC segment under temporary pressure from **soft realizations** and **elevated inventory costs**, driven by steep PVC price declines and seasonal monsoon-related offtake weakness. ## C. Derivatives & Specialty * **Core Revenue Driver:** Derivatives and specialty business now represents majority revenue share, reflecting strategic shift toward higher-value products. ## D. Chlorotoluene Progress * **Commercial Traction:** Chlorotoluene shipments have moved beyond samples to **full truckload deliveries**, though ramp-up remains gradual amid customer supply chain transitions. * **Growth Horizon:** Management expects **sizable revenue contribution by FY '27**, with margins tracking initial targets. ## E. ECH & Hydrogen Peroxide * **Technology Shift:** Global ECH capacity expansion is increasingly glycerin-based; propylene route now limited to legacy assets in the **West and Korea**. --- # 3. Volume & Utilization ## A. Key Figures * **Plant Utilization:** **78%** Q3 FY26 (flat QoQ, down from 81% YoY) · **76%** 9M FY26 (vs. 82% prior year) * **Revenue:** **₹1,807 Cr** 9M FY26 (–7% YoY) * **Chlorine Integration:** **70–75%** as of Q3 * **ECH & PVC Utilization:** **Above 50%** (improved QoQ) ## B. Plant Utilization * **Near-Term Utilization Pressure:** Subdued capacity utilization across core plants drove a **7% YoY revenue decline**, despite sequential stabilization in Q3. * **Improving Momentum:** Utilization trends turned positive from mid-November, with expectations of **continued recovery** in upcoming quarters. * **New Plant Outlook:** Initial ramp-up for the new CPVC plant (targeting Q2 FY27 commissioning) is expected to be **subdued in Year 1**, with optimal utilization projected within **1–2 years** due to strong domestic demand. * **Execution Uncertainty:** Management highlights **high uncertainty in long-term utilization forecasts** due to commissioning delays and teething issues, urging caution on forward-looking assumptions. ## C. Volume Recovery * **Volume Rebound Underway:** Volumes showed flat to marginal quarterly improvement, with **discernible growth since mid-November** driven by better plant utilization. * **Chlorotoluene Gaining Traction:** Volumes rising MoM and QoQ, though contribution remains limited; **meaningful uplift expected from Q1 next fiscal**. * **Stable Realizations:** No significant change in product pricing, with realizations holding at prior levels. ## D. New Project Timeline * **Pilot Plant Accelerates Innovation:** A **multi-chemistry pilot plant** is under construction to support customer development in chlorotoluene derivatives, CPVC, and future products, reducing time-to-market and enhancing quality. --- # 4. Pricing & Input Costs ## A. Key Figures * **CPVC Realization:** **₹95–100/kg** (slight QoQ decrease) * **ECU:** **₹29,000–30,000/ton** (down marginally QoQ) · Expected **₹30,000–31,000/ton** in coming months * **ECH Realization:** **₹160–170/kg** ## B. CPVC Realizations * **PVC Cost Pass-Through:** CPVC pricing pressure easing as PVC prices bottom out and begin rising; expected margin recovery with **1–5 month lag** in realization adjustments. * **Stable Realizations:** CPVC, caustic soda, and hydrogen peroxide prices show only minor fluctuations (~**1,000 units**) despite input volatility, indicating pricing discipline. ## C. ECU Dynamics * **ECU Formula Constraint:** ECU is strictly determined by **caustic sales minus chlorine prices**, with no direct benefit from integration level; at **75% integration**, **25% exposure** leads to ~**₹7,000 loss** when ECU is at ₹30,000. * **Downside Risks:** Near-term ECU outlook faces pressure from potential **Chinese import dumping** and **rising domestic capacity**, despite rupee depreciation not providing offsetting advantage. ## D. Global Price Shifts * **Upward Price Momentum:** Global chemical prices are rising in Q3/Q4 due to stronger demand, supported by **China’s removal of export rebates on 250 products** and higher petrochemical inputs. * **Glycerin-Driven ECH Inflation:** **65% of global ECH** production is glycerin-based (biodiesel byproduct), making prices tightly linked; **no new propylene-based capacity** enhances Asian price sensitivity, with **~one-quarter lag** to glycerin cost moves. --- # 5. Customer & Market Access ## A. Key Figures * **CPVC Demand:** **280,000 tonnes** FY '26E · **320,000 tonnes** FY '27E * **CPVC Demand Growth:** **10%–12%** annual growth expected ## B. Customer Approvals * **Progress Amid Volume Delays:** Significant advancement in end-user product approvals achieved, though volume ramp-up remains constrained by **phased customer transition** and building confidence. * **Revenue Timing:** Chlorotoluene revenue visibility awaits finalization of **approvals and contracts in Q1 FY '27**, after which guidance will be updated. ## C. Export Volumes * **China Export Shift:** Reduced Chinese export benefits combined with **favorable currency dynamics** (yuan up, rupee down) enhance domestic manufacturing competitiveness. * **Regional Export Trends:** U.S. ECH exports remain **minimally impacted** due to limited prior exposure; European volumes are recovering following **permanent closures** of competitor plants. ## D. Contract Progression * **Near-Term Contracting:** Current orders remain on a **quarterly basis**, with long-term contracts anticipated only from **FY '27 onwards**. ## E. Demand Resilience * **Recovery in Core Demand:** Performance weakness in H2 FY '26 attributed to **prolonged monsoon and soft demand**, now reversed with **improved demand momentum** entering Q4. * **Resilient CPVC Trends:** CPVC demand demonstrates strength despite seasonal disruptions, with **volume growth sustained** and **full absorption expected** of new capacity due to robust market consumption. * **Near-Term Uptick:** Demand volumes expected to rise in Q4, with **seasonal uptrend forecast for January–February**. --- # 6. Risks & Industry Challenges ## A. Key Figures * **Chlorine Price:** **~₹7,000** (current negative price) ## B. Pricing Volatility * **Temporary Pressure:** Pricing headwinds in Q3 attributed to transient global conditions, with expectations of normalization as market absorption offsets new capacity within 1–2 years. * **Input Cost Divergence:** Caustic soda prices expected to decline due to excess supply, while chlorine prices anticipated to rise post-commissioning of new plants. * **Economic Drag:** Current negative chlorine pricing exerts margin pressure despite integration advantages. ## C. Competitive Entry * **High Barriers to CPVC Production:** Entry into CPVC resin manufacturing is hindered by technical complexity, capital intensity, and a required shift from B2C to B2B operating models, limiting credible threats from pipe-focused players. * **Strategic Differentiation:** Management emphasizes that B2C-oriented firms like Astral are likely to prioritize core businesses over venturing into capital- and expertise-intensive chemical production. * **Integrated Entrants:** New caustic soda capacity from Adani and Reliance—backed by chlorine-consuming PVC operations—will contribute to surplus caustic soda supply. ## D. Macro Headwinds * **Mixed Sector Performance:** Chemical markets show divergence, with select segments under pressure from monsoon delays, geopolitical tensions, weak exports, and trade policy stagnation. * **Prolonged Global Pressure:** Industry faced nine months of subdued realizations due to adverse international dynamics, though recent trends suggest stabilization. * **Sustained ECH Cost Pressure:** Lack of global policy support for biodiesel—amplified by **Trump’s stance**—to keep glycerin and consequently ECH prices elevated in near-term outlook. * **Stable Chlor-Alkali Outlook:** Despite new capacity additions, Indian chlor-alkali fundamentals remain resilient due to rising domestic demand and staggered plant startups. --- # 7. Guidance & Outlook ## A. Key Figures * **Capex Spend:** **₹337 Cr** ## B. FY27 Revenue Growth * **Strategic Shift to High-Value Segments:** Targeting **70% revenue contribution from derivatives and specialty businesses**, driven by diversification and integrated complex expansion. * **Growth Inflection Ahead:** Material revenue acceleration expected from **FY29 onwards**, supported by new projects and value chain extensions, with FY27 poised for recovery on higher volumes. * **Demand Recovery in Sight:** Improvement expected in next fiscal year versus a weak first half in FY26, though timing varies by product; chlorotoluene plant commissioning in March 2025 to boost FY27+ earnings. ## C. Margin Recovery * **CPVC Margin Rebound Underway:** Margins expected to trend back toward **24%–25%** range as PVC raw material costs stabilize and inventory normalizes; Q4 seen improving on Q3. ## D. Capex Plans * **Capacity Doubling on Track:** CPVC and ECH expansion progressing within timeline and budget, aligned with 5–7 year demand outlook from real estate and epoxy resin sectors. * **No Forward Integration into Epoxy:** Despite ECH expansion, company to remain upstream, capitalizing on strong external demand and sector capacity growth. ## E. Strategic Milestones * **New Chemistry Announcement Imminent:** Expected within next two months, likely by FY-end, as finalization is in advanced stage. * **Focus on Sustainable Value Creation:** Emphasis on scalable, profitable growth with disciplined capital allocation; clearer FY28 guidance expected by March.